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Abstract During the last decade, the development
of transcatheter based therapies has provided feasible
therapeutic options for patients with symptomatic
severe valvular heart disease who are deemed inop-
erable. The promising results of many nonrandom-
ized series and recent landmark trials have increased
the number of percutaneous transcatheter valve proce-
dures in high operative risk patients. Pre-procedural
imaging of the anatomy of the aortic or mitral valve
and their spatial relationships is crucial to select the
most appropriate device or prosthesis and to plan the
percutaneous procedure. Multidetector row computed
tomography provides 3-dimensional volumetric data
sets allowing unlimited plane reconstructions and
plays an important role in pre-procedural screening
and procedural planning. This review will describe
the evolving role of multidetector row computed
tomography in patient selection and strategy planning
of transcatheter aortic and mitral valve procedures.
Keywords Transcatheter heart valve implantation 
Computed tomography  Imaging
Introduction
During the last decade, the development of trans-
catheter based therapies has provided feasible ther-
apeutic options for patients with symptomatic severe
valvular heart disease who are deemed inoperable.
The promising results of many nonrandomized series
and recent landmark trials, such as the PARTNER
trial with the Edwards SAPIEN transcatheter aortic
valve prosthesis (Edwards Lifesciences, Irvine, CA,
USA) or the EVEREST II trial with the MitraClip
device (Abbott Vascular, Structural Heart, Menlo
Park, CA, USA), have increased the number of
percutaneous transcatheter valve procedures in high
operative risk patients [1, 2].
In contrast to open heart surgery where direct
inspection of the valve is possible, the decision for
device/prosthesis selection and planning of the per-
cutaneous procedure is mainly based on pre-proce-
dural imaging of the anatomy of the aortic or mitral
valve and their spatial relationships. These data are
usually acquired using 2-dimensional (2D) imaging
modalities such as conventional echocardiography
and/or invasive angiography. However, 2D echocar-
diography imaging relies on geometrical assumptions
that may reduce the accuracy of the measurements
while ﬂuoroscopy has limited soft-tissue resolution.
In contrast, advanced cardiovascular imaging modal-
ities such as multidetector row computed tomography
(MDCT), provide detailed information on the afore-
mentioned anatomy. MDCT, which has the advantage
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unlimited plane reconstructions, plays an important
role in pre-procedural screening and procedural
planning with the aim of minimizing procedural-
related complications. This review will describe the
evolving role of MDCT in patient selection and
strategy planning of transcatheter aortic and mitral
valve procedures.
Transcatheter aortic valve implantation
Transcatheter aortic valve implantation (TAVI) has
emerged as an effective alternative in high risk
patients with symptomatic severe aortic stenosis
(AS). Recently, this percutaneous intervention has
demonstrated superior survival at 1 year over stan-
dard therapy (69.3% vs. 49.3%, with an absolute 20%
increase with TAVI procedure) in a selected group of
patients with AS who were deemed not suitable for
aortic valve surgery [1]. In addition, a recent review
involving more than 2,000 patients receiving TAVI
reported an implantation success of 94% and a 30-day
survival rate of 89% [3]. Accurate assessment of the
anatomy of the peripheral arteries and aorta, together
with the anatomy of the aortic valve, aortic annular
and root dimensions, are the key determinants of
procedural feasibility and safety.
Pre-procedural patient evaluation
The multidisciplinary pre-procedural evaluation of
patients who are candidates for TAVI includes the
assessment of the aortic valvular complex, including
the aortic valve and aortic root (for determination of
anatomical suitability and prosthesis sizing), and the
anatomy of the peripheral arteries and aorta (for
determination of the access site) (Table 1).
First, assessment of the aortic valve should begin
with conﬁrmation of the aortic valve morphology.
Usually, this can easily be identiﬁed from the short-
axis view on transthoracic echocardiography, which
remains the initial modality of choice to assess the
aortic valve pathology and its hemodynamic conse-
quences [4]. However, in patients with poor acoustic
windows and/or in the presence of heavy calciﬁca-
tion, differentiating tricuspid from bicuspid valvular
anatomy may be challenging [5]. This information is
important before the procedure as it is currently not
recommended to perform TAVI on bicuspid valves
due to the potential risk of an unfavorable deploy-
ment [6, 7]. In a recent study of 50 patients with AS
(17 bicuspid and 33 tricuspid) [8], transthoracic
echocardiography was unable to identify the anatomy
of the valve in 10 patients (20%) due to extensive
calciﬁcation. In contrast, MDCT was able to provide
direct visualisation of the aortic valve and thus could
correctly identify the valve anatomy in 49 of 50 cases
(98%) [8]. Furthermore, the accuracy of the patient
selection process can be further improved with
additional systolic reconstruction using ECG-gating,
which permits differentiation between a bicuspid
valve with raphe and a tricuspid valve [9].
Next, the assessment of the extent and location of
the aortic valve calciﬁcation is important before the
TAVI procedure. With high spatial resolution and the
possibility of direct visualization of the aortic valve,
MDCT allows detailed analysis of the quantiﬁcation
and localization of aortic valve calciﬁcation (Fig. 1).
Several studies [10–12] have indicated the signiﬁ-
cance of aortic valve calciﬁcation and its speciﬁc
location, as assessed by MDCT, in relation to the
presence of post-procedural aortic regurgitation. For
example, in a study of 100 patients who underwent
TAVI with self-expandable devices, John et al. [11]
demonstrated a strong linear correlation (r = 0.86,
P\0.001) between the degree of aortic regurgitation
immediately post-TAVI and the severity of calciﬁ-
cation in the device ‘‘landing zone’’, deﬁned as the
area extending from the left ventricular outﬂow tract
to the aortic valvular cusps. Similar ﬁndings were
reported in a series of 53 patients undergoing TAVI
[10] whereby moderate post-procedural aortic regur-
gitation following the implantation of balloon-
expandable valves was found in patients who exhib-
ited more calciﬁcation of the native aortic valves,
especially at the valve commissures (Fig. 1). It has
been suggested that bulky calciﬁcation may pose
resistance during the deployment of the prosthesis,
resulting in paravalvular leakage arising from the gap
between the prosthesis and the native valve [13]. In
addition, very bulky calciﬁcation at the edge of native
valvular leaﬂets has been related to increased risk of
coronary occlusion when it is displaced over the
coronary ostium [14]. Furthermore, TAVI has to be
performed with caution when there is heavy calciﬁ-
cation in the sinotubular junction as it may cause
restriction during balloon expansion at the aortic end,
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time of deployment [15]. Hence, appreciation of the
extent and location of calciﬁcation, more precisely
measured using MDCT, may help to anticipate and
thus avoid potential procedural complications.
Besides its implications on the procedural outcome
of TAVI, the assessment of aortic valve calciﬁcation
can be a useful adjunct in the evaluation of AS
severity during pre-procedural screening [16, 17]. In
a recent study, the degree of aortic valve calciﬁcation
Table 1 Evaluation before transcatheter aortic valve implantation: anatomic requirements of the currently available prosthesis
Anatomy CoreValve revalving system Edwards SAPIEN XT
26 mm 29 mm 23 mm 26 mm
Peripheral arteries and aorta
Iliofemoral artery diameter (mm) C6 (18 Fr) C6 (18 Fr) C6.5 (19 Fr)
Tortuosity
Calciﬁcation
Aortic valve
Anatomy
Calciﬁcation
Annular diameter (mm) 20–23 24–27 18–22 21–25
Aortic root
Sinus of Valsalva diameter (mm) C27 C28 NA
Sinotubular junction diameter (mm) B40 B43 NA
Ascending aorta diameter (mm) B43 NA
Height of the coronary ostia from the
aortic annular plane (mm)
C10 C8
Left ventricular septal thickness (mm) \17 NA
Coronary artery anatomy Not in severe proximal coronary lesions
not amenable to revascularization
Not in severe proximal coronary lesions
not amenable to revascularization
Intracardiac thrombus Absent Absent
Fig. 1 Aortic valve calciﬁcation assessed using multidetector
row computed tomography (MDCT): implications for trans-
catheter aortic valve implantation. a shows a calciﬁed tricuspid
aortic valve with bulky calciﬁcation mainly in the left cusp,
left–right commissure and extending to the base of the anterior
mitral valve leaﬂet (indicated by arrows in b). Following
TAVI, paravalvular leak was observed with colour Doppler
transesophageal echocardiography in the long-axis view
(c) that coincided with the location of bulky calciﬁcation at
the left–right commissure on MDCT (in a). In this example, the
bulky calciﬁed cusp and commissure might pose resistance
during transcatheter prosthesis deployment, resulting in
subsequent paravalvular leak (arising from the gap between
the prosthesis and native valve). LA left atrium, RV right
ventricle
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the hemodynamic severity of AS measured using
echocardiography [16].
Accurate evaluation of the aortic valve annular
dimension is key for appropriate selection of pros-
thesis size. This process is unique in percutaneous
procedures as direct inspection of the valve is not
possible. Currently, the Edwards SAPIEN XT device
is available in two sizes: 23 mm valve for aortic
annulus between 18 and 22 mm and 26 mm valve for
aortic annulus between 21 and 25 mm. Similarly, the
Medtronic CoreValve system has two sizes: 26 mm
valve for aortic annulus between 20 and 23 mm and
29 mm valve for aortic annulus between 24 and
27 mm (Table 1)[ 18]. This step is critical as
inaccurate sizing will result in undesirable peri-
procedural consequences such as prosthesis migra-
tion, signiﬁcant aortic regurgitation (if undersized) or
rupture of the aortic root (if oversized). In most
centers, the measurement of the aortic annular
diameter is performed using 2D echocardiography.
In clinical practice, it is widely recognised that the
aortic annulus is deﬁned at the lowest attachment
point of the aortic valve leaﬂets within the left
ventricle (LV), forming a virtual ring [19]. As
previously shown, this functional ring is not circular
but oval in shape (Fig. 2), and is more accurately
visualized with 3D imaging techniques [20, 21]. In a
recent study of patients undergoing open aortic valve
surgery, Smı ´d et al. [22] compared pre-operative
measurements of the aortic annulus using MDCT,
magnetic resonance imaging (MRI) and 2D trans-
esophageal echocardiography. Using intra-operative
direct measurement as the reference, the accuracy of
pre-operative measurement using either MDCT or
MRI were superior compared to echocardiographic
measurement, highlighting the high precision achiev-
able with MDCT [22]. This is partly due to the high
spatial resolution of MDCT which permits improved
visualization of the aortic valve. Another explanation
is that the anatomical planes of measurement
obtained with different modalities are not identical
[23, 24]. For example, the parasternal long-axis view
for transthoracic or transesophageal echocardiogra-
phy represents an oblique cut through the aortic
annulus and provides a single annular dimension that
usually does not correspond to a true anatomical
diameter measurement (either the maximum or
minimum diameter visualised on MDCT) (Fig. 2).
Given that the aortic annulus is oval in shape, only
3D imaging techniques can provide the most accurate
assessment of the aortic annulus dimension. As such,
MDCT permits reconstructions in unlimited planes,
allowing multiple measurements of the aortic annulus:
minimum (Dmin), maximum (Dmax), mean (Dmean =
[Dmin ? Dmax]/2) diameters and cross-sectional areas
(Fig. 2)[ 21, 25]. Depending on how the aortic
annulus is measured, the selection of the prosthesis
size may differ. For example, in a recent study of 75
patients with severe AS undergoing MDCT as part
of procedural planning for TAVI, Schultz and
co-workers [25] showed that ineligibility for the
currently available Medtronic CoreValve system
differed substantially if Dmin or Dmax were used.
Thus, 26 or 39% of patients would not qualify for
TAVI with Medtronic CoreValve system due to too
small or too large annular dimensions, respectively. In
50 patients who subsequently received the Medtronic
Fig. 2 Aortic valve annular dimensions. Multidetector row
computed tomography (MDCT) permits excellent visualization
of the oval-shaped aortic annulus with correct alignment of the
orthogonal multiplane reformation planes (a and b). The
correct aortic annular plane is deﬁned at the lowest attachment
point of all the three valve leaﬂets (c) and multiple
measurements of the aortic annulus can be made: minimum
(Dmin), maximum (Dmax), mean (Dmean = [Dmin ? Dmax]/2)
diameters and cross-sectional areas (CSA)
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the best agreement with the operator choice (n = 37,
74%), whereas the agreement with the operator choice
was only 44 or 32% if Dmin or Dmax were used,
respectively [25]. For the Edwards SAPIEN prosthe-
sis, Messika-Zeitoun et al. [26] reported that using
Dmean, as measured by MDCT, would have changed
the prosthesis size in 38% of patients. Prospective
studies examining the value of different imaging
modalities in sizing of prosthesis and its immediate
impact on procedural outcomes are lacking but are
important to establish the gold standard methodology
to size the aortic valve annulus and select the
prosthesis size.
In addition, the assessment of the dimensions of the
sinus of Valsalva, sinotubular junction and ascending
aorta is an essential step in the pre-procedural
evaluation. Using the ‘‘center-line approach’’ and
reformations of the aortic root and ascending aorta,
MDCT permits accurate measurement of these
dimensions. This information is critical especially
in patients undergoing the self-expandable device
implantation as a dilated aortic root/ascending aorta
is currently a contraindication (Table 1)[ 6].
Next, the 3D analysis of MDCT permits compre-
hensive and detailed evaluation of the spatial rela-
tionship of the aortic valve with the surrounding
structures. In particular, the information on the height
of the coronary ostia relative to the aortic annular
plane is important to ensure patency of the coronary
arteries following ballooning and deployment of the
transcatheter prosthesis (Fig. 3). Currently, a mini-
mum distance of 10 mm is recommended for both
devices [18]. In addition, MDCT is an ideal modality
to measure the length of the valvular leaﬂets as it can
potentially increase the risk of coronary occlusion,
notably in patients with bulky calciﬁcation of the
aortic leaﬂets (Fig. 3b) [14]. However, this require-
ment may vary from individual to individual as the
ﬁnal position of the prosthesis depends on the
interaction between the prosthesis and the aortic
annulus [15].
Fig. 3 Assessment of the height of the coronary ostia relative
to the aortic annular plane. Multidetector row computed
tomography (MDCT) permits accurate orientation of the aortic
annular plane (a) and precise measurement of the distance
between the left and right coronary ostia and the annular plane
(b and c). In addition, the length of the valvular leaﬂet,
measured from the aortic annulus to the cusp tip, can be
obtained on MDCT (red arrow in b)
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and aortic anatomy is fundamental to plan the
procedural strategy: retrograde (through a transarte-
rial approach, transfemoral or transsubclavian) or
antegrade (through a transapical approach). Although
recent advances have allowed for a lower crimped
proﬁle delivery device, the transfemoral approach for
self- or balloon-expandable systems can only be con-
sidered when the minimal diameter of the iliofemoral
vessel is C6 mm (to accommodate a 18F sheath size)
[27]. As adequate access is one of the most important
determinants of procedural success [28], the decision
for selecting the transfemoral approach relies on the
precise measurement of vessel dimension, tortuosity
and calciﬁcation of the peripheral arteries and aorta
[6]. In the recent multicenter SOURCE registry of
1,038 patients who received a balloon-expandable
prosthesis, the rate of vascular complications with the
transfemoral approach was higher (22.9% vs. 4.7%)
when compared with the transapical approach, high-
lighting the need for careful patient selection, to
select the most suitable procedural approach to avoid
procedural-related vascular complications [29].
Although conventional angiography is the refer-
ence method to assess the luminal diameter, tortuos-
ity and calciﬁcation of the peripheral arteries and
aorta [6], true cross-sectional diameters and areas are
better visualized on MDCT. Typically, the curved
multiplanar reformation planes (MPR), using the
‘‘center-line approach’’, permits reconstruction of the
curved planes, following the course of the vessel
regardless of its tortuous course. Ideally, the precise
measurement of the vascular structures should be
obtained from the axial view, perpendicular to the
long axis of the vessel (Fig. 4c, d). In the presence of
calciﬁcation, the blooming effect has to be brought to
a low level when these measurements are being
performed.
With the 3D volume rendering images, current
MDCT techniques permit rotation and display to best
deﬁne the total number and severity of angulations
along the vessel of interest. Post-processing imaging
software is available to detect all angulations along
the vessel automatically and allows precise measure-
ment of the severity of angulations (Fig. 4e), which
helps to systematically quantify the extent of tortu-
osity in patients who are being considered for a
transfemoral procedure. In addition, MDCT can
accurately delineate the location and the extent of
calciﬁcation along the vessel. This is particularly
important in case of a tortuous vessel as signiﬁcant
calciﬁcation does not allow straightening of the
vessel during advancement of the sheath and should
prompt the consideration of an alternative access
(either the transapical or transsubclavian approach).
Furthermore, severe calciﬁcation at the bifurcation of
the iliac vessels may become a concern for the
transfemoral approach as it may restrict sheath
advancement and increase the risk of vessel perfora-
tion or dissection. In a recent study by Kurra et al.
[30] that examined 100 patients who were considered
for TAVI, as many as 35% of patients had unsuitable
iliofemoral anatomy deﬁned as one of the following:
minimal diameter of the iliofemoral vessel \8m m
(a requirement for the older generation delivery
system), [60% circumferential calciﬁcation at the
external-internal iliac bifurcation or severe angulation
\90. Among those with MDCT criteria of unsuit-
able anatomy (n = 35), 5 patients proceeded with
transfemoral-TAVI. Of these 5 patients, 2 (40%) had
vascular complications requiring surgical interven-
tion [30].
Besides the anatomical requirement of the ilio-
femoral arteries, the pre-procedural assessment of the
aorta and its lumen is necessary as it may guide the
approach of TAVI. Presence of bulky atherosclerosis
of the aorta, a porcelain aorta, a transverse course of
the ascending aorta or a previous aorto-femoral
bypass is a contraindication for the transfemoral
approach [6]. Fluoroscopy, commonly used to eval-
uate the luminal diameter of the peripheral arteries,
does not allow accurate assessment of arterial wall
disease or atherosclerotic plaques. In contrast, MDCT
provides a comprehensive evaluation including arte-
rial luminal diameter and wall assessment. The pres-
ence of extensive aortic atherosclerosis as detected
with MDCT may preclude the transfemoral approach
due to the increased risk of cerebrovascular events
during manipulation of the catheters along the
diseased aorta.
Although suitable vessel anatomy is the key
consideration in the transfemoral approach, other
aspects need to be considered, which may favour one
approach over another. For instance, pericardial
calciﬁcation, a deformed chest wall anatomy or
severe pulmonary disease may make the transapical
approach unsuitable and MDCT is helpful to provide
such information.
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Pre-operative CT has been demonstrated to accu-
rately predict the location of the aortic valve and
ascending aorta relative to the chest wall in patients
undergoing a minimally invasive approach for aortic
valve replacement [31]. Several groups have reported
that 3D data obtained from MDCT can help to predict
the ﬂuoroscopic projections that are optimal for
TAVI procedures [32–34]. An ideal angiographic
plane (the so called ‘‘implanter’s view’’) should be
the projection that aligns all three aortic cusps in a
straight line, perpendicular to the aortic valve plane
(Fig. 5)[ 15]. A recent study by Gurvitch et al. [32]
compared 2 groups of patients who underwent
TAVI with (20 patients) and without (20 patients)
pre-procedural MDCT. When MDCT information
was available to guide the ﬂuoroscopic projection
angle, an excellent or satisfactory ﬁnal implant
projection was achieved in 90% of cases (n = 18),
as compared to only 65% of cases (n = 13) when
pre-procedural MDCT was not available [32].
With regard to the transapical approach, the
relation of the LV apex and the aortic annulus plane
(the so called ‘‘ventriculo-aortic angle’’) can be
important (Fig. 6). Recently, the ﬁrst-in-man series
of a new self-expanding prosthesis implantation via
the transapical approach was reported in 30 patients
[35]. The initial experience highlighted the impor-
tance of this ventriculo-aortic angle, which may pose
as a challenge during the introduction of a straight
and rigid delivery system (via the LV apex) which
Fig. 4 Evaluation of peripheral arteries with multidetector
row computed tomography (MDCT). a shows an example of
infrarenal aorta, iliac and femoral arteries in a 3-dimensional
volume rendering view. Using the center-line approach, the
curved multiplanar reformation (MPR) permits reconstruction
of the curved planes, following the course of the vessels.
Subsequently, the true cross-sectional internal diameter and
area of the iliac artery can be measured from the double
oblique transverse view in (c and d). With the current MDCT
post-processing imaging software (3mensio Valves
TM, version
4.2., 3mensio Medical Imaging BV, Bilthoven, The Nether-
lands), the minimum diameter threshold required for the
currently available transfemoral devices is 6 mm (18 Fr) and
this minimum requirement is simultaneously displayed side-
by-side in the curved MPR views (b). Therefore, the presence
of a minimal luminal diameter of the iliofemoral arteries
\6 mm does not favor the transfemoral approach. In contrast,
the example in d shows a vessel with a minimal luminal
diameter[6 mm, as indicated by the dotted green circle which
is larger than the size of a simulated 18 Fr sheath (in solid red
circle). In addition, the 3-dimensional reconstruction volume
rendering technique of MDCT allows rotations and displays the
tortuous course of the iliofemoral arteries. e gives the precise
measurement of one of the angulations seen in the left external
iliac artery (51), rendering it unsuitable for the transfemoral
approach
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patients to a risk of aortic dissection when the device
is advanced into the ascending aorta [35]. Novel 3D
based post-processing imaging software is currently
available to permit direct visualization of this ventri-
culo-aortic relationship to aid in the planning for the
Fig. 5 Planning of angiographic planes. Using reformation
reconstruction of multidetector row computed tomography
(MDCT), the appropriate aortic valve plane for transcatheter
aortic valve implantation can be anticipated (a). The ideal
angiographic projection should be one that aligns all the three
aortic cusps in a straight line, perpendicular to the aortic valve
plane (b). LCC left coronary cusp, NCC non-coronary cusp,
RCC right coronary cusp
Fig. 6 Assessment of the left ventricular geometry may be of
relevance in the planning of the transapical approach. The
relation of the left ventricular apex and the aortic annulus valve
plane (the so called ‘‘ventriculo-aortic angle’’) can be reliably
measured on multidetector row computed tomography
(MDCT). Insert a shows the direction of a simulated delivery
system through the left ventricular apex, towards the aortic
valve. In addition, the thickness of the left ventricular septum
wall can be measured on MDCT (arrow in insert b). Post-
processing imaging software (3mensio Valves
TM, version 4.2.,
3mensio Medical Imaging BV, Bilthoven, The Netherlands)
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the angulation required during insertion of the apical
sheath and the delivery system, towards the direction
of the aortic valve and the ascending aorta (Fig. 6). In
addition, the measurement of the LV septal wall
thickness with MDCT is important (Fig. 6b) as the
presence of severe sigmoid basal septum may pre-
vent stable positioning of the deployed prosthesis
(Table 1).
Other factors to be considered before TAVI
In addition to the aforementioned considerations,
additional factors need to be evaluated before TAVI,
which completes the pre-procedural screening. The
evaluation of coronary artery anatomy is mandatory
as the presence of signiﬁcant coronary artery disease
needs to be revascularized. Current position state-
ment does not recommend TAVI in patients with
severe proximal coronary stenoses not amenable to
percutaneous coronary interventions [6]. Although
MDCT has shown its diagnostic accuracy in the
evaluation of coronary artery disease [36], the
prevalence of coronary atherosclerosis in the elderly
population may limit its accuracy in detecting
signiﬁcant coronary artery stenoses. Therefore, inva-
sive coronary angiography remains the reference
modality to evaluate the coronary anatomy in this
highly selected group of patients [6].
Finally, LV dimensions, function and the presence
of concomitant mitral regurgitation (MR) need to be
evaluated before TAVI. This information is usually
available from the standard echocardiography, which
is still the initial imaging modality in patients
scheduled for TAVI. However, in patients with poor
acoustic window, MDCT allows assessment of LV
dimensions and function using ECG-gating. More
importantly, it permits detection of intracardiac
thrombus, which is an established contraindication
for TAVI (Table 1)[ 6].
Transcatheter mitral valve repair procedures
Mitral valve repair is the treatment of choice for
patients with symptomatic MR [4]. Advances in
surgical techniques have led to improved clinical
results in young and elderly patients [37]. However,
associated comorbidities and low LV ejection
fraction increase the operative morbidity and mortal-
ity risks in the elderly population and may lead to
non-referral or denial for surgery in as many as 50%
of the patients with symptomatic severe MR [38].
Transcatheter-based and minimally invasive sur-
gical therapies have been developed over the last
years. Several therapeutic options are now available
for patients with symptomatic severe MR and high
operative risk. These percutaneous techniques can be
classiﬁed as leaﬂet-based (edge-to-edge repair,
Mitraclip device [Abbott Vascular, Structural Heart,
Menlo Park, CA, USA]), coronary sinus or mitral
annulus-based (Carillon, Monarc or Viacor devices
and Quantum cor and Mitralign devices, respectively)
and LV-based (Coapsys device [Myocor, Maple
Grove, MN]). The EVEREST II trial has shown the
feasibility, safety and efﬁcacy of the Mitraclip device
in reducing MR and improving clinical symptoms
[39]. In addition, initial experiences with devices
designed to reduce the mitral annulus perimeter and
improve the mitral leaﬂet coaptation (the AMADEUS
and the EVOLUTION trials) demonstrated that trans-
catheter mitral restrictive annuloplasty approaches
may be a feasible alternative to surgery in selected
patients [40–42]. Furthermore, the results of the
RESTORE-MV trial showed that patients with func-
tional MR beneﬁted from ventricular reshaping with
the Coapsys device, with signiﬁcant improvement in
clinical symptoms and survival [43].
The feasibility and efﬁcacy of these transcatheter-
based or minimally invasive surgical therapies rely on
the presence of suitable valve and LV anatomy and
geometry. Evaluation of the underlying mechanism of
MR is crucial to select the most appropriate trans-
catheter based therapy (Table 2). In brief, MR can be
divided into organic or primary MR when the mitral
valve itself is diseased (i.e. Barlow’s disease, healed
infective endocarditis) and secondary or functional
MR when the mitral valve is anatomically normal but
a remodeled and dysfunctional LV prevents adequate
coaptation of the mitral leaﬂets. Two-dimensional and
recently, 3D transesophageal echocardiography are
the mainstay imaging techniques used in surgical
decision-making (mitral valve repair or replacement).
However, the high spatial resolution of MDCT
permitsaccurate assessment of the anatomy, geometry
and spatial relationships of the mitral valve complex
and thus provides important information for selecting
candidates for these therapies.
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The Mitraclip device is delivered to the mitral valve
via percutaneous femoral venous transseptal puncture
and creates a double-oriﬁce valve, resulting in
improved mitral leaﬂet coaptation and MR reduction.
After crossing the interatrial septum, the delivery
system is steered toward the mitral valve plane and
the clip is aligned perpendicular to the mitral leaﬂets
and centered in the area with the largest effective
regurgitant oriﬁce area. Afterwards, the delivery
system is advanced into the LV and the arms of the
clip are opened for subsequent grasping and coapta-
tion of the leaﬂets at the targeted scallops.
Transesophageal echocardiography plays a central
role in pre-procedural screening and procedural
guidance during the intervention. Current 3D trans-
esophageal echocardiography permits visualization of
the mitral valve from multiple perspectives, orienta-
tion of the MPR to localize the largest regurgitant
oriﬁce and accurate characterization of the underly-
ing mechanism of MR. Similarly, MDCT enables
accurate 3D visualization of the mitral leaﬂets and
detailed evaluation of the anatomic criteria essential
in percutaneous Mitraclip implantation:
– Central regurgitant jet, located at the central
scallops of the anterior (A2) and posterior (P2)
mitral leaﬂets.
– Coaptation length C2 mm and coaptation depth
B11 mm (for functional MR).
– ﬂail gap \10 mm and ﬂail width \15 mm (for
organic MR).
Multidetector row computed tomography data
reconstructed in smaller (such as 5%) increments
throughout the RR interval provide high spatial
resolution images with improved temporal resolution
and enable identiﬁcation of the systolic frame where
mitral leaﬂet coaptation failure occurs.
In addition, MDCT provides information on the
underlying mechanism of MR. For example, the
diagnostic performance of MDCT to identify mitral
valve prolapse was recently evaluated in a series of
53 patients [44]. The orientation of the MPR across
the mitral valve plane provides the LV 4-, 2- and
3-chamber apical views and enables localization of
the mitral valve prolapse, billowing and ﬂail leaﬂet
(Fig. 7). The sensitivity, speciﬁcity, positive predic-
tive value and negative predictive value of MDCT for
diagnosis of mitral valve prolapse were 96, 93, 93
and 96%, respectively [44]. Furthermore, the assess-
ment of the mitral valve geometry and the measure-
ment of the tenting heights (coaptation depth) and
leaﬂet angles can be accurately performed in patients
with functional MR [45]. The orientation of the
orthogonal MPR across the modiﬁed short-axis view
of the mitral valve provides the 4-chamber view at
the anterolateral (A1–P1), central (A2–P2) and pos-
teromedial (A3–P3) levels (Fig. 8). In a series of 67
heart failure patients, including 29 patients with
signiﬁcant functional MR, the mitral valve geometry
was evaluated with MDCT [45]. In patients with
signiﬁcant MR, the maximum tenting height and
tethering of the posterior mitral leaﬂet were located at
the central and posteromedial levels. The knowledge
of these data beforehand permits accurate planning of
the procedural strategy and may result in a signiﬁcant
shortening of ﬂuoroscopy and procedure timings.
MDCT before coronary sinus annuloplasty
Coronary sinus-based mitral annuloplasty devices
have been designed to treat functional MR percuta-
neously. Two anchors or stents connected by a bridge
Table 2 Transcatheter-based mitral valve repair techniques
Mitral valve repair technique Device Trial Indication
Leaﬂet repair MitraClip EVEREST I
EVEREST II
Organic mitral valve regurgitation
Functional mitral valve regurgitation
Coronary sinus-based annuloplasty Carillon
Monarc
PTMA
AMADEUS
EVOLUTION
PTOLEMY-1
Functional mitral valve regurgitation
Direct LV remodelling Coapsys RESTOR-MV Functional mitral valve regurgitation
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123element are placed within the distal part of the
coronary sinus or the great cardiac vein and in the
coronary sinus ostium. The bridging connector con-
straints the coronary sinus and reduces the antero-
posterior diameter of the mitral annulus, improving
the coaptation of the mitral leaﬂets and reducing the
MR. Data from the AMADEUS trial have demon-
strated the feasibility, safety and efﬁcacy of this
therapy [42]. Out of 48 heart failure patients enrolled
with signiﬁcant functional MR, 30 patients received
the Carillon device (Cardiac Dimensions, Inc., Kirk-
land, WA). At 6 months follow-up, signiﬁcant reduc-
tions in regurgitant volume, effective oriﬁce
regurgitant area and vena contracta were observed,
together with signiﬁcant improvements in clinical
status [40]. However, one of the main concerns of this
therapy is the possibility of impingement of the
epicardial coronary arteries. In 17% of implants, a
signiﬁcant arterial impingement involving the cir-
cumﬂex coronary artery was observed. In addition, an
Fig. 7 Evaluation of underlying mechanism of mitral regur-
gitation with multidetector row computed tomography
(MDCT). Mitral valve prolapse can be identiﬁed accurately
with MDCT. a shows an example of a patient with prolapse of
the posterior leaﬂet (arrow). Color Doppler echocardiography
permits quantiﬁcation of the regurgitant volume and the
direction of the regurgitant jet (b). Modiﬁed with permission
from Feutchner et al. [44]
Fig. 8 Mitral valve geometry assessment with multidetector
row computed tomography (MDCT) in functional mitral
regurgitation. From the short-axis view of the mitral valve at
the level of the mitral leaﬂets and commissures, the orthogonal
planes across the anterolateral (A1–P1), central (A2–P2) and
posteromedial (A3–P3) provide the apical views of the mitral
valve apparatus and permits the measurement of the leaﬂet
angles and tenting heights (arrows)
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123insufﬁcient change in MR grade was observed in 4
patients. The variable position and course of the
coronary sinus relative to the mitral annulus is one of
the determinants of the efﬁcacy of this therapy.
Multidetector row computed tomography provides
useful information on the dimensions of the coronary
sinus and its position relative to the mitral annulus
and the circumﬂex coronary artery [46–48]. Com-
bining the axial views and 3D volume renderings,
MDCT permits evaluation of the feasibility and
safety of coronary sinus-based mitral annuloplasty
procedures (Fig. 9). Tops et al. [47] evaluated the
dimensions, course and spatial relationships of the
coronary sinus in 105 patients undergoing MDCT. In
90% of patients, the coronary sinus was superior to
the mitral valve annulus with a distance that ranged
between 1.4 and 16.8 mm. Importantly, this distance
was signiﬁcantly larger in patients with heart failure
as compared to controls (6.2 ± 3.4 mm vs. 4.4 ±
3.4 mm, P\0.05). Therefore, in a signiﬁcant num-
ber of patients the coronary sinus coursed along the
posterior wall of the left atrium rather than along
the mitral annular plane reducing the efﬁcacy of
this device to improve MR. In addition, in 68% of
Fig. 9 Multidetector row computed tomography (MDCT)
prior to coronary sinus-based mitral valve annuloplasty.
Combination of 3-dimensional volume rendering and axial
views of the mitral valve annulus permit assessment of the key
anatomic relationships of the coronary sinus: its position
relative to the mitral annular plane and the circumﬂex coronary
artery. a shows an example of a patient with the coronary sinus
properly aligned with the mitral annulus (as seen with the
3-dimensional volume rendering). However, at the level of the
distal part of the coronary sinus, where the distal anchor is
positioned, the circumﬂex coronary artery courses between the
mitral annulus and the coronary sinus. The risk of coronary
impingement in this example may contraindicate the proce-
dure. In contrast, b shows an example where the coronary sinus
courses superiorly to the posterior mitral annulus. The coronary
sinus-based mitral annuloplasty may be less effective in this
case, since the tension is applied to the posterior wall of the left
atrium rather than the mitral annulus. In addition, there is a
potential risk of circumﬂex coronary artery compromise as the
distal part of the coronary sinus courses over the artery
(arrow). CS coronary sinus, CX left circumﬂex artery
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123patients, the circumﬂex coronary artery coursed
between the coronary sinus and the mitral annulus,
indicating an increased risk of arterial impingement
during percutaneous coronary sinus-based annulo-
plasty. This information can be also obtained with
MRI, a valuable alternative to MDCT in patients with
severe renal dysfunction in whom the use of iodinated
contrast may be contraindicated [49].
MDCT before direct LV remodeling
The RESTOR-MV trial evaluated the efﬁcacy of the
Coapsys device (Myocor, Inc., Maple Grove, MN) in
reducing MR and improving clinical outcomes of
heart failure patients with functional MR undergoing
surgical revascularization [43]. This device is placed
without the need of cardiopulmonary bypass and aims
to reduce the mitral valve annular dimensions and
correct the displacement of the papillary muscles.
The anterior and posterior pads are positioned on the
epicardial surface of the heart and the expanded
polytetraﬂuoroethylene-coated subvalvular cord that
connects both pads is tightened under echocardio-
graphic guidance until signiﬁcant reduction or elim-
ination of MR is achieved [50]. Several anatomic and
geometric criteria determine the eligibility for this
procedure. Presence of structural abnormality of the
mitral valve apparatus (i.e. leaﬂet prolapse, chordal
rupture, mitral annular calciﬁcation or calciﬁed
leaﬂets) and LV end-diastolic diameter [70 mm
contraindicate this procedure. In addition, the poten-
tial interference with the papillary muscles or the
inability to avoid main epicardial coronary arteries
during device positioning may inﬂuence the feasibil-
ity of this treatment.
As previously mentioned, MDCT provides accu-
rate characterization of the LV dimensions, anatomy
and location of the papillary muscles and location
and extent of mitral valve apparatus calciﬁcation [45,
51]. Furthermore, the position of the anterior and
posterior pads can be anticipated during pre-proce-
dural screening, by visualizing the position of the
main epicardial coronary arteries in the 3D volume
renderings. Compared to the group of patients
undergoing surgical coronary artery bypass grafting
alone or in combination with mitral valve repair, the
RESTOR-MV showed a signiﬁcant improvement in
MR, LV systolic function and survival of patients
with ischemic heart failure and functional MR [43].
Conclusions
Accurate selection of patients who are candidates for a
transcatheter-basedvalverepair/implantationtechnique
results in high success rates and reduces the number of
procedural complications. MDCT should play a central
role in both aortic and mitral transcatheter-based
interventionsasitprovidesacomprehensiveassessment
oftheanatomypriortotheprocedureandhelpstoselect
the most appropriate procedural approach, making the
procedureassafeaspossible.Inaddition,theuseofstate
of the art scanners and dose modulation MDCT
protocols can potentially optimise the iodined-based
contrast load and reduce the radiation exposure.
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